[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amnestic-mild-cognitive-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amnestic-mild-cognitive-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100473568","phase-2-pathways-relating-amnestic-mci-to-a-mild-traumatic-brain-injury-history-100473568",false,"NCT05446584","Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History","PATH","Inclusion Criteria:\n\n1. Active diagnosis of amnestic mild cognitive impairment\n2. Presence of an mTBI history for the mTBI+ group; absence of an mTBI history for a control sample\n3. Female and male subjects\n4. All races\u002Fethnicities\n5. Age 55 years and older\n6. Fluent in English\n\nExclusion Criteria:\n\n1. Mild traumatic brain injury within past year\n2. Lifetime history of moderate or severe brain injury\n3. Lifetime major neurologic syndromes (e.g., stroke, epilepsy, brain tumor)\n4. Lifetime major cardiovascular conditions (e.g., heart attack, heart failure)\n5. Current substance use disorder\n6. Current major psychiatric disorders (e.g., major depressive disorder, bipolar disorder)\n7. Current vision or hearing impairment that interferes with testing\n8. Any electronic and or metallic implants in the skull or brain\n9. Current medication use known to alter HD-tDCS reactivity","ALL","55 Years",{"count":19,"type":20},75,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study will probe if the biological changes in amnestic mild cognitive impairment (aMCI) are related to a history of mild traumatic brain injury (mTBI) using high definition transcranial direct current stimulation (HD-tDCS) and blood-derived biomarker tools. Participants who Do as well as those who Do Not have a history of mTBI will be enrolled in the study.",[26,27,28,29,30],"Mild Cognitive Impairment","Amnestic Mild Cognitive Disorder","Amnestic Mild Cognitive Impairment","Mild Traumatic Brain Injury","Concussion, Brain",[32,33,34,35,36],"MCI","TBI","memory","biomarker","Alzheimer","RECRUITING","2026-07-16",{"date":40,"type":41},"2026-07-20","ACTUAL",{"date":43,"type":41},"2023-04-20",{"date":45,"type":20},"2027-05-31",{"name":47,"class":48},"University of Texas Southwestern Medical Center","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":71,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":49},"100265889","molecular-and-structural-imaging-in-alzheimers-disease-a-longitudinal-study-100265889","NCT02740634","Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study","Inclusion Criteria:\n\n* Over the age of 21\n* Must have an informant who will be able to provide independent evaluation of functioning\n* English is primary language\n* All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).\n* All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language\n* All subjects with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain\n\nExclusion Criteria:\n\n* If you have had a stroke or tumor that could explain your symptoms\n* Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study\n* Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded\n* Subjects will be excluded if they have poor vision (20\u002F400)\n* Women that are pregnant or post-partum and breast-feeding will be excluded\n* Subjects will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome\n* Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy)","21 Years","80 Years",{"count":59,"type":20},60,[61],"NA","This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.",[64,65,66,67,68,69,70,27],"Atypical Alzheimer's Disease","Logopenic Progressive Aphasia (LPA)","Posterior Cortical Atrophy (PCA)","Alzheimer Disease","Alzheimer Disease, Early Onset","Amnestic Disorder","Amnestic Symptoms",[72,73,74,75],"PCA","LPA","AD","Amnestic AD",{"date":77,"type":41},"2026-07-17",{"date":79,"type":4},"2016-05",{"date":81,"type":20},"2027-03",{"name":83,"class":48},"Mayo Clinic",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":57,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":49},"100550245","modified-ketogenic-diet-in-amnestic-mild-cognitive-impairments-100550245","NCT06444568","Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments","Efficacy of Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments","Inclusion Criteria:\n\n* Having been diagnosed with \"amnestic mild cognitive impairment\u002Fdisorder (aMCI)\" by the clinician after the evaluation of cognitive functions according to the neuropsychological evaluation method (0.5 according to the Clinical Dementia Rating Scale (CDR).)\n* Having at least 6 years of education.\n\nExclusion Criteria:\n\n* Under the age of 65 or over the age of 80.\n* Diagnosis of neurological (other than MCI) or psychological diseases.\n* GDS-15 score \\> 5 (baseline)\n* Kidney\u002Fpancreas\u002Fliver diseases or dysfunctions, Type 1 diabetes (and Type II diabetic patients receiving insulin replacement therapy), cancer, metabolic diseases (fatty acid oxidation defect, etc.), thyroid dysfunction, pulmonary or autoimmune diseases, head trauma, history of any cardiovascular event (i.e., stroke, myocardial infarction) in the last year.\n* Hypercholesterolemia (fasting T-C \\>300 mg\u002FdL or LDL-C \\>200 mg\u002FdL), non-reference B12 or folate levels according to biochemical tests performed in the last year.\n* Nutritional risks (chewing\u002Fswallowing difficulties, history of involuntary weight loss in the last 6 months, body mass index \\\u003C 22 kg\u002Fm2).\n* Use of internal device\u002Fimplant (pacemaker or hearing aid, etc.).\n* Medication use (individuals using anticholinergic, antidementia, and opioid class drugs will be excluded; individuals using antidepressant class drugs will be included in the study on the condition that it has been continued for at least 3 months and there is no change in drug type and dose during the study protocol.)","65 Years",{"count":93,"type":20},36,[61],"This clinical study aims to examine the effectiveness of a 12-week modified ketogenic diet (MKD) intervention, especially on cognitive functions, in individuals diagnosed with amnestic-mild cognitive impairment (aMCI) and to compare the effects of control groups (passive or active).\n\nAccordingly, a sample of 36 older adults aged 65-80 years diagnosed with aMCI will be randomized into 3 different groups: passive control (without any intervention), active control (MIND: Mediterranean-DASH Intervention for Neurodegenerative Delay diet) or intervention (MKD). They will be monitored according to targeted criteria throughout the 12-week study protocol.\n\nThe main questions this study aims to answer are:\n\n* Does a 12-week MKD intervention improve cognitive functions in aMCI?\n* Does the effectiveness of the 12-week MKD intervention in aMCI (i.e., in terms of cognitive function, physical and functional measures, or metabolic\u002Finflammatory biomarkers) differ from control groups?\n\nExpected from participants during the study protocol:\n\n* Participants assigned to the passive control arm are expected to come to the research center at the beginning (week 0) and end (week 12) of the protocol and participate in evaluations.\n* Participants assigned to the active control (MIND diet) or intervention (MKD) arm are expected to adhere to assigned dietary therapy, keep a weekly food diary, and have weekly phone calls or online meetings with the dietitian to follow up on the diet. These participants assigned to the diet groups are expected to come to the research center at weeks 0, 4, 8, and 12 to participate in the evaluations.",[27,28],"2024-11-20",{"date":99,"type":41},"2024-11-25",{"date":101,"type":41},"2024-05-20",{"date":103,"type":20},"2025-03-01",{"name":105,"class":48},"Saglik Bilimleri Universitesi"]